Stoke Therapeutics (STOK) Cash & Equivalents Growth (3y) (2021 - 2026)

Stoke Therapeutics (STOK) Cash & Equivalents Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Stoke Therapeutics 1.86 Bn 1.52 Bn - -6.48%

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.48%
Dec 31, 2025 -9.48%
Sep 30, 2025 -9.74%
Jun 30, 2025 14.41%
Mar 31, 2025 48.39%
Dec 31, 2024 -4.05%
Sep 30, 2024 0.22%
Jun 30, 2024 4.60%
Mar 31, 2024 -12.60%
Dec 31, 2023 -12.66%
Sep 30, 2023 -0.26%
Jun 30, 2023 -1.66%
Mar 31, 2023 -3.42%
Dec 31, 2022 -20.08%
Sep 30, 2022 -21.35%
Jun 30, 2022 -34.64%
Mar 31, 2022 -5.18%
Dec 31, 2021 11.19%
Sep 30, 2021 97.43%